Latest news with #PhenoCycler-Fusion
Yahoo
23-05-2025
- Business
- Yahoo
Spatial Omics Market Set to Reach USD 1,308.88 Million by 2032, Driven by Rising Demand for Precision Medicine and Technological Breakthroughs
SNS Insider Unveils Strategic Insights into the U.S. Spatial Omics Market's Sudden Growth—Worth USD 144.38 Million in 2023—While the U.S. Dominates More Than 81% of Global Share During Revolutionary Biotech Developments. Austin, May 23, 2025 (GLOBE NEWSWIRE) -- Spatial Omics Market Size & Growth Analysis: According to SNS Insider, the global Spatial Omics Market was valued at USD 451.76 million in 2023 and is anticipated to reach USD 1,308.88 million by 2032 and grow at a CAGR of 12.55% over the forecast period of 2024–2032. The US led the market in 2023, accounting for over 81% of the share. The demand is propelled by the increasing utilization of precision medicine and the necessary detailed molecular tissue-level knowledge. As the scientific and medical community is seeking a more comprehensive view of disease pathogenesis and cellular architecture, spatial omics is emerging as an essential contributor to this, providing next-generation insights through high-resolution gene and protein expression mapping, particularly in oncology and a Sample Report of Spatial Omics Market@ Market Overview Spatial omics is a powerful molecular biology method that integrates genomics, transcriptomics, and proteomics with spatial information for gaining new insights at the single-cell and sub-cellular level. It maintains the spatial information of biomolecules within tissue, which can be used to understand the heterogeneity of disease, tumor microenvironment, and immune response. This power is revolutionizing how diseases are investigated and treated. Especially in the U.S., academia and biopharma are making big bets on spatial biology tools in efforts to advance drug discovery and personalized treatment plans, supported by healthy funding and collaborations. Major Players Analysis Listed in this Report are: 10x Genomics (Visium Spatial Gene Expression, Xenium In Situ Gene Expression) Akoya Biosciences, Inc. (PhenoCycler-Fusion, Phenoptics) Bio-Techne (RNAscope, Advanced Cell Diagnostics - RNAScope) Bruker Corporation (MALDI Imaging, TIMS-TOF Pro) Dovetail Genomics (Cantata Bio.) (Hi-C, Micro-C) Illumina, Inc. (NextSeq 1000, NovaSeq 6000) Ionpath, Inc. (MIBI, MIBI-TOF) NanoString Technologies, Inc. (GeoMx Digital Spatial Profiler, nCounter Analysis System) RareCyte, Inc. (CyteFinder System, CyteJet) Vizgen, Inc. (MERSCOPE, MERFISH) Advanced Cell Diagnostics, Inc. (RNAscope, BaseScope) Biognosys AG (SpectroMine, Panorama) Fluidigm Corporation (CyTOF, Helios) Lunaphore Technologies S.A. (PhenoImager, PhenoCycler) Molecular Machines & Industries GmbH (Molecular Machine Imaging System, Spatial Protein Profiling) PerkinElmer, Inc. (Vectra Polaris, Opera Phenix) Rebus Biosystems, Inc. (REBUS Imaging Platform, REBUS Scanning Technology) Standard BioTools Inc. (CellStream, IonFlux) Zeiss Group (ZEISS LSM 980, ZEISS Axio Imager) GE Healthcare (Inveon PET, Discovery MI) Spatial Omics Market Report Scope Report Attributes Details Market Size in 2023 US$ 451.76 Million Market Size by 2032 US$ 1,308.88 Million CAGR CAGR of 12.55% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By product, the consumable segment was the largest in 2023, and the fact that consumables are used in repeated experiments favored the dominance of the segment. Instruments are expected to be the most rapidly growing segment, favored by the requirement of automation in sensing devices with high-resolution spatial sensing capabilities. FFPE samples accounted for 60.7% share, and are also preferred due to stability and abundant presence in biobanks. Fresh frozen is quickly evolving as more samples are being acquired because of their suitability for high-resolution molecular profiling. The technology market, led by spatial transcriptomics (40.9% market share), is rising, with spatial proteomics being adapted because of its capabilities for mapping protein interactions. Diagnostics led applications, with 49.4%, while drug discovery was the fastest growing use case, fueled by pharma investment in precision biology. Workflow and End-user Analysis Workflow-wise, instrumental analysis accounted for the highest share with a 43.8% in 2023, such as imaging and sequencing technologies used for spatially linked data. Data analysis is now the fastest-growing workflow, as there is a growing need for AI and machine learning tools to make sense of complex, multi-modal datasets. Academic and translational research facilities led demand among end-users, with 40.8% of the market, backed by government funding and partnerships. The pharmaceutical and biotech industry is the largest and fastest-growing user of spatial omics applications in the clinical trial, biomarker discovery, and drug development pipeline space. This change suggests an emerging market in which research results are moving more and more into actual therapy development. Regional Trends The largest share of the global spatial omics market in 2023 was held by North America (39.7%) due to early adoption of technology development, the presence of a large number of academic and research institutes, and R&D funding from the public and private sectors. The USA is still dominating in innovation thanks to contributions of biotech companies, research institutions, and clinical laboratories. Asia Pacific, in the meantime, is the most promising region, owing to the rise in governments` investments in spatial biology research projects in countries like South Korea, Japan, and China. This demand is also boosted by government-funded precision medicine programmes and a burgeoning biotechnology industry. Europeans are also jumping on the spatial omics bandwagon in cancer and neurodegenerative disease research, particularly in Germany, the United Kingdom, and the Nordic nations. Buy a Single-User PDF of Spatial Omics Market Analysis & Outlook Report 2024-2032@ Recent Developments Illumina announced in February 2025 a spatial transcriptomics tech, only a few months in advance was capable of resolving millions of cells per experiment, while the capture area is nine times greater and the resolution four times higher than systems. It is expected to be launched commercially in 2026. In January 2025, University of Pennsylvania researchers introduced an AI tool called MISO (Multi-modal Spatial Omics), which can help make sense of tiny tissue samples for personalized cancer diagnostics. 10x Genomics in December 2024 introduced the Xenium Analyzer Plus, an updated spatial imaging platform with increased multiplexing for concurrent RNA and protein detection. In November 2024, NanoString Technologies and Thermo Fisher Scientific partnered to jointly develop spatial multi-omic panels for FFPE samples. Statistical Insights and Trends Reporting Globally, over USD 1.5 billion was invested in spatial biology research from all funding sources, with North America contributing to approximately 48% of this funding as a result of federal grants and biotech venture capital. 27% of new, non-redundant oncology solution-initiating trials in 2023 included spatial omics data, a 60% increase from 2020. The US is leading the world in trial-based adoption. Adoption of spatial omics in the academic lab is estimated to increase from 900 installations in 2023 to more than 3,200 by 2032 worldwide, an increase of 4‐fold in spatial technology implementation. Spatial transcriptomics and proteomics, combined, produced more than 1.2 petabytes of data in 2023, with more than 65% of the analysis being executed in the cloud with bioinformatics tools. The cost to perform a typical spatial omics operation was USD 480 per sample in 2023 and is anticipated to decrease to less than USD 300 in 2027 through automation of the platform and reagent standardization. Spatial Omics Market Segmentation By Product Instruments Sequencing Platforms IHC Microscopy Flow Cytometry Mass Spectrometry Others Consumable Software Bioinformatics Tools Imaging Tools Storage & Management Databases By Sample Type Formalin-Fixed Paraffin-Embedded (FFPE) Fresh Frozen By Technology Spatial Transcriptomics Spatial Genomics Spatial Proteomics By Application Diagnostics Translation Research Cell Biology Single Cell Analysis Others By Workflow Sample Preparation Instrumental Analysis Data Analysis By End-use Academic & Translational Research Institutes Pharmaceutical & Biotechnology Companies Contact Research Organizations (CROs) Others Need Any Customization Research on Spatial Omics Market, Enquire Now@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 6. Competitive Landscape 7. Spatial Omics Market by Product 8. Spatial Omics Market by Sample Type 9. Spatial Omics Market by Technology 10. Spatial Omics Market by Application 11. Spatial Omics Market by Workflow 12. Spatial Omics Market by End-use 13. Regional Analysis 14. Company Profiles 15. Use Cases and Best Practices 16. Conclusion Related Reports Single-Cell Analysis Market to Triple by 2032, Reaching $10.27B with 13.61% CAGR Single-Cell Omics Market Set for Explosive Growth to $6.21B by 2032, CAGR of 16.2% Consumer Genomics Market to Surge to $10.8B by 2032, Driven by 24.6% CAGR Bioinformatics Market Forecast to Reach $35.38B by 2032, Growing at 13.38% CAGR About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Akoya Biosciences Reports First Quarter 2025 Financial Results
MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ('Akoya'), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. 'Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals,' said Brian McKelligon, CEO of Akoya Biosciences. 'As we look ahead to combining forces with Quanterix, we are confident in the value-creating opportunities this integration brings—uniting two leaders in proteomics to accelerate the future of precision medicine.' First Quarter 2025 Financial Results Revenue was $16.6 million in the first quarter of 2025, compared to $18.4 million in the prior year period; a decrease of 9.8%. Gross margin was 59.3% in the first quarter of 2025, compared to 45.7% in the prior year period. Operating expenses were $23.3 million for the first quarter of 2025, compared to $30.0 million in the prior year period, an improvement of 22.3%. Operating loss was $13.4 million for the first quarter of 2025, compared to $21.6 million in the prior year period, an improvement of 37.9%. Net cash used in operating activities decreased by $13.6 million to $7.2 million in the first quarter of 2025, compared to $20.8 million in the prior year period. $27.5 million of cash, cash equivalents and marketable securities as of March 31, 2025. First Quarter 2025 Business Highlights Akoya and Team SAMBAI announced the selection of PhenoCycler-Fusion as the foundational spatial proteomics platform for a landmark Cancer Grand Challenges-funded study. This large-scale study aims to address cancer inequities through high-plex, high-throughput spatial analysis and will generate data for a first-of-its-kind Biobank and Data Repository. Akoya and the Singapore Translational Cancer Consortium (STCC) have partnered to deploy the PhenoCode Discovery IO60 panel in the SUPER study, aimed at advancing cancer immunophenotyping in Singapore. The study seeks to identify predictors of PD-1 immunotherapy response in real-world Asian patient populations, bridging cutting-edge spatial proteomics with clinical insights. At the recent American Association for Cancer Research (AACR) Annual Meeting (April 25–30, Chicago, IL), Akoya in partnership with Enable Medicine, launched the largest commercially available single-cell spatial proteomics atlas. Akoya also announced the expansion of its Advanced Biopharma Solutions portfolio with a new antibody-drug conjugate (ADC) breast cancer assay and showcased real-world insights from the IO60 panel. The quarter ended with an instrument installed base of 1,359 (410 PhenoCyclers, 949 PhenoImagers), a year-over-year increase of 12.0% compared to an installed base of 1,213 (354 PhenoCyclers, 859 PhenoImagers) in the prior year period. The quarter ended with 1,891 total publications citing Akoya's technology, a year-over-year increase of 44.7% compared to 1,307 total publications in the prior year period. In light of the pending acquisition by Quanterix Corporation, Akoya will not be hosting an earnings conference call or providing forward-looking guidance at this time. Important Additional Information In connection with its proposed acquisition of Akoya (the 'Merger'), Quanterix Corporation ('Quanterix') will file with the SEC a post-effective amendment to its previously filed registration statement on Form S-4 (as so amended, the 'Registration Statement'), which will contain a preliminary proxy statement of Akoya and a preliminary prospectus of Quanterix (the 'Proxy Statement/Prospectus'), and each of Quanterix and Akoya have, and may in the future, file with the SEC other relevant documents regarding the proposed Merger. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE PROXY STATEMENT/PROSPECTUS CAREFULLY AND IN THEIR ENTIRETY AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BY QUANTERIX AND AKOYA, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT QUANTERIX, AKOYA AND THE PROPOSED MERGER. A definitive copy of the Proxy Statement/Prospectus will be mailed to Akoya stockholders when that document is final. Investors and security holders will be able to obtain the Registration Statement and the Proxy Statement/Prospectus, as well as other filings containing information about Quanterix and Akoya, free of charge from Quanterix or Akoya or from the SEC's website when they are filed. The documents filed by Quanterix with the SEC may be obtained free of charge at Quanterix's website, at or by requesting them by mail at Quanterix Investor Relations, 900 Middlesex Turnpike, Billerica, MA 01821. The documents filed by Akoya with the SEC may be obtained free of charge at Akoya's website, at or by requesting them by mail at Akoya Biosciences, Inc., 100 Campus Drive, 6th Floor, Marlborough, MA 01752 ATTN: Chief Legal Officer. Participants in the Solicitation Quanterix and Akoya and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Akoya in respect of the proposed Merger. Information about Akoya's directors and executive officers is available in the Proxy Statement/Prospectus and in Amendment No. 1 to Akoya's Annual Report on Form 10-K for fiscal year ended December 31, 2024, filed with the SEC on April 28, 2025, and other documents filed by Akoya with the SEC. Other information regarding the persons who may, under the rules of the SEC, be deemed participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Proxy Statement/Prospectus and other relevant materials to be filed with the SEC regarding the proposed Merger when they become available. Investors should read the definitive Proxy Statement/Prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from Quanterix or Akoya as indicated above. No Offer or Solicitation This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval with respect to the Merger, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. Forward-Looking Statements This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding the potential benefits of the pending acquisition of Akoya by Quanterix Corporation and the likelihood that such acquisition will be consummated, Akoya's ability to achieve market acceptance of, and the potential and capabilities of, its current and planned products and services, and other statements regarding Akoya's growth prospects, business strategies, operational performance, use of capital, results of operations, financial position and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents Akoya files with the Securities and Exchange Commission from time to time. Akoya cautions you that forward-looking statements are based on a combination of facts and factors currently known by Akoya and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Akoya's views as of the date hereof. Akoya undertakes no obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events for any reason, except as required by law. All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Akoya's underlying assumptions prove to be incorrect, actual results may differ materially from what Akoya anticipates. Akoya cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. About Akoya Biosciences As The Spatial Biology Company®, Akoya Biosciences' mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit Investor Contact: Priyam Shahinvestors@ Media Contact: Ritu Mihani media@ BIOSCIENCES, INC. AND SUBSIDIARYCondensed Consolidated Balance Sheets (in thousands) March 31, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 20,357 $ 11,779 Marketable securities 7,187 23,261 Accounts receivable, net 11,742 13,779 Inventories, net 22,853 24,321 Prepaid expenses and other current assets 4,073 3,592 Total current assets 66,212 76,732 Property and equipment, net 6,920 7,203 Demo inventory, net 1,119 1,336 Intangible assets, net 13,845 14,559 Goodwill 18,262 18,262 Operating lease right of use assets, net 3,859 4,255 Financing lease right of use assets, net 1,307 1,525 Other non-current assets 1,125 1,133 Total assets $ 112,649 $ 125,005 Liabilities and Stockholders' (Deficit) Equity Current liabilities Accounts payable, accrued expenses and other current liabilities $ 21,863 $ 19,607 Current portion of operating lease liabilities 2,708 2,674 Current portion of financing lease liabilities 506 609 Deferred revenue 6,518 6,554 Current portion of long-term debt, net of debt discount 76,487 — Total current liabilities 108,082 29,444 Deferred revenue, net of current portion 2,782 3,063 Long-term debt, net of current portion and debt discount — 76,182 Contingent consideration liability, net of current portion 3,472 3,871 Operating lease liabilities, net of current portion 3,406 3,988 Financing lease liabilities, net of current portion 616 693 Other long-term liabilities 180 169 Total liabilities 118,538 117,410 Total stockholders' (deficit) equity (5,889 ) 7,595 Total liabilities and stockholders' (deficit) equity $ 112,649 $ 125,005AKOYA BIOSCIENCES, INC. AND SUBSIDIARYConsolidated Statements of Operations (in thousands, except share and per share amounts) Three months ended March 31, March 31, 2025 2024 Revenue: Product revenue $ 12,032 $ 12,140 Service and other revenue 4,607 6,210 Total revenue 16,639 18,350 Cost of goods sold: Cost of product revenue 4,491 6,723 Cost of service and other revenue 2,277 3,248 Total cost of goods sold 6,768 9,971 Gross profit 9,871 8,379 Operating expenses: Selling, general and administrative 17,580 19,863 Research and development 5,557 5,554 Change in fair value of contingent consideration 146 179 Impairment — 2,971 Restructuring — 1,397 Total operating expenses 23,283 29,964 Loss from operations (13,412 ) (21,585 ) Other income (expense): Interest expense (2,492 ) (2,612 ) Interest income 313 937 Other expense, net (13 ) (161 ) Loss before provision for income taxes (15,604 ) (23,421 ) Provision for income taxes (48 ) (63 ) Net loss $ (15,652 ) $ (23,484 ) Net loss per share attributable to common stockholders, basic and diluted $ (0.32 ) $ (0.48 ) Weighted-average shares outstanding, basic and diluted 49,664,515 49,188,170 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24-04-2025
- Business
- Yahoo
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
>8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data available MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient, cellular and molecular data, today announced a groundbreaking collaboration to deliver the largest commercially available single-cell spatial proteomics atlas to the research and clinical community. Enable Medicine's Pan-Cancer Atlas is a unique multi-modal dataset built using Akoya's PhenoCycler®-Fusion (PCF) platform and includes the PhenoCode™ Discovery IO60 panel as its foundational data. The Enable Atlas comprises over 100 million single cells, spanning 8,500+ samples and 15+ cancer types, with rich cellular features, including up to 60 protein biomarkers, accompanying H&E images and spatial transcriptomics measurements, and comprehensive clinical metadata. The Enable Atlas is curated, standardized, and commercially licensable. It provides immediate value to biopharma researchers and AI model developers seeking to accelerate biomarker discovery, drug development, and translational insights. It is a special mechanism for new and existing PhenoCycler-Fusion customers to further power their experiments by integrating their data with the Enable Atlas. 'The Enable Atlas is a catalytic resource for our customers,' said Niro Ramachandran, Chief Business Officer at Akoya Biosciences. 'Biopharma customers now have the potential to generate new hypotheses from existing data, increase the statistical power of their studies, and identify novel cellular phenotypes at a scale never before possible.' Built for scale. Designed for discovery. The Enable Atlas's spatial proteomics layer was generated using Akoya's PhenoCycler-Fusion, the industry's fastest and most scalable spatial biology platform, and included the ultrahigh-plex IO60 panel, capturing broad biological diversity across tissue types. Enable Medicine's software platform hosts the dataset and makes it easily explorable, allowing users to filter and subset by biomarker expression, tissue type, clinical metadata, and more. These analytical and annotation capabilities make the Atlas a powerful tool for biomarker discovery, comparative analysis, and statistical validation in discovery and translational research. 'Our strategy to map disease and provide insightful biological data requires technologies that scale. PhenoCycler-Fusion and IO60 made this possible — this combination uniquely powered the generation of our large, high-resolution, and biologically rich proteomic dataset,' said Aaron Mayer, Chief Scientific Officer at Enable Medicine. 'This level of multiplexing, throughput, and consistency was essential to create a resource that's not only comprehensive but immediately impactful in therapeutic, diagnostic, and scientific research settings.' Key features of the Enable Pan-Cancer Atlas: Unmatched scale and depth: Over 100 million spatially profiled single cells High-dimensional data: up to 60 protein markers with spatial context, H&E, and spatial transcriptomics data on select samples Diverse sample coverage: 8,500+ samples across 15+ cancer indications and normal tissues Rich metadata: Clinical context to power translational insights Immediate usability: Licensable and structured for downstream analysis Meet Us at AACR 2025 The Spatial Atlas will be showcased at the upcoming American Association for Cancer Research (AACR) Annual Meeting, offering attendees a first look at this new spatial proteomics resource. Location: Akoya Booth #3045 | April 27 | 4:30–5:00 PM A live demonstration of the Atlas will be available during the scheduled session. Members of the Akoya and Enable Medicine teams will be on-site to discuss how the dataset can be applied to translational research, biomarker discovery, and drug development programs. For more information, visit About Akoya Biosciences As The Spatial Biology Company®, Akoya Biosciences' mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit About Enable Medicine Enable Medicine is a real-world data company unlocking new insights into human disease via integrated patient, cellular and molecular information. The company offers AI-ready biological data, data management tools and data analysis services to fuel the development of large multimodal foundational models, diagnostics and drug development. Enable Medicine's data solutions support science spanning the discovery of novel therapeutic targets to assist with better clinical trial design. To learn more about Enable, visit Akoya Forward-Looking Statements This press release contains forward-looking statements that are based on Akoya management's beliefs and assumptions and on information currently available to Akoya management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements concerning the capabilities and potential of Akoya's products and services, its collaboration with Enable Medicine, its future performance and its plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents Akoya files with the Securities and Exchange Commission from time to time. The reader is cautioned that forward-looking statements are based on a combination of facts and factors currently known by Akoya and Akoya's projections of the future, about which Akoya cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Akoya's views as of the date hereof. Akoya undertakes no obligation to update any forward-looking statements for any reason, except as required by law. Investor Contact: Priyam Shah investors@ Media Contact: Ritu Mihani media@ Enable Medicine Business Development Contact: Jess Werlin bd@
